全文获取类型
收费全文 | 24594篇 |
免费 | 6269篇 |
国内免费 | 138篇 |
专业分类
耳鼻咽喉 | 700篇 |
儿科学 | 713篇 |
妇产科学 | 837篇 |
基础医学 | 881篇 |
口腔科学 | 2698篇 |
临床医学 | 4501篇 |
内科学 | 5982篇 |
皮肤病学 | 491篇 |
神经病学 | 2231篇 |
特种医学 | 1062篇 |
外科学 | 4244篇 |
综合类 | 93篇 |
现状与发展 | 12篇 |
一般理论 | 2篇 |
预防医学 | 2916篇 |
眼科学 | 438篇 |
药学 | 422篇 |
中国医学 | 8篇 |
肿瘤学 | 2770篇 |
出版年
2024年 | 135篇 |
2023年 | 1097篇 |
2022年 | 365篇 |
2021年 | 655篇 |
2020年 | 1232篇 |
2019年 | 529篇 |
2018年 | 1365篇 |
2017年 | 1315篇 |
2016年 | 1542篇 |
2015年 | 1608篇 |
2014年 | 2007篇 |
2013年 | 2471篇 |
2012年 | 876篇 |
2011年 | 837篇 |
2010年 | 1421篇 |
2009年 | 2009篇 |
2008年 | 828篇 |
2007年 | 638篇 |
2006年 | 772篇 |
2005年 | 586篇 |
2004年 | 464篇 |
2003年 | 402篇 |
2002年 | 370篇 |
2001年 | 514篇 |
2000年 | 405篇 |
1999年 | 496篇 |
1998年 | 549篇 |
1997年 | 522篇 |
1996年 | 563篇 |
1995年 | 423篇 |
1994年 | 333篇 |
1993年 | 283篇 |
1992年 | 283篇 |
1991年 | 266篇 |
1990年 | 246篇 |
1989年 | 240篇 |
1988年 | 216篇 |
1987年 | 200篇 |
1986年 | 196篇 |
1985年 | 193篇 |
1984年 | 158篇 |
1983年 | 165篇 |
1982年 | 130篇 |
1981年 | 115篇 |
1980年 | 91篇 |
1979年 | 121篇 |
1978年 | 97篇 |
1977年 | 95篇 |
1976年 | 81篇 |
1974年 | 88篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
Maaike van Gerwen MD Naomi Alpert MS Raja Flores MD Emanuela Taioli MD PhD 《American journal of industrial medicine》2020,63(2):115-120
The association between asbestos exposure, mainly in occupational settings, and malignant mesothelioma has been well established; this has prompted several countries to establish mesothelioma epidemiologic surveillance programs often at the request of national agencies. This review compares currently existing mesothelioma registries worldwide to develop a concept model for a US real-time case capture mesothelioma registry. Five countries were identified with a mesothelioma specific registry, including Italy, France, UK, Australia, and South Korea. All, except the UK, used interviews to collect exposure data. Linkage with the national death index was available or was in future plans for all registries. The registries have limited information on treatment, quality of life, and other patient-centered outcomes such as symptoms and pain management. To thoroughly collect exposure data, “real-time” enrollment is preferable; to maximize the capture of mesothelioma cases, optimal coverage, and a simplified consent process are needed. 相似文献
4.
Chie Teramoto PHN RN MS Satoko Nagata PhD PHN RN Reiko Okamoto PhD PHN RN Ruriko Suzuki PHN RN MS Emiko Kishi PhD PHN RN Michie Nomura DSN PHN RN Noriko Jojima PHN RN MS Masumi Nishida PhD PHN RN Keiko Koide PhD PHN RN Emiko Kusano PhD PHN RN Saori Iwamoto PhD PHN RN Sachiyo Murashima PhD PHN RN 《Public health nursing (Boston, Mass.)》2015,32(6):654-661
5.
Joseph Wheatley Zhengyang Liu Joel Loth Mark P. Plummer Jahan C. Penny-Dimri Reny Segal Julian Smith Luke A. Perry 《Acta anaesthesiologica Scandinavica》2023,67(2):131-141
Background
Patients undergoing cardiac surgery are at significant risk of developing postoperative acute kidney injury (AKI). Neutrophil–lymphocyte ratio (NLR) is a widely available inflammatory biomarker which may be of prognostic value in this setting.Methods
We conducted a systematic review and meta-analysis of studies reporting associations between perioperative NLR with postoperative AKI. We searched Medline, Embase and the Cochrane Library, without language restriction, from inception to May 2022 for relevant studies. We meta-analysed the reported odds ratios (ORs) with 95% confidence intervals (CIs) for both elevated preoperative and postoperative NLR with risk of postoperative AKI and need for renal replacement therapy (RRT). We conducted a meta-regression to explore inter-study statistical heterogeneity.Results
Twelve studies involving 10,724 participants undergoing cardiac surgery were included, with eight studies being deemed at high risk of bias using PROBAST modelling. We found statistically significant associations between elevated preoperative NLR and postoperative AKI (OR 1.45, 95% CI 1.18–1.77), as well as postoperative need for RRT (OR 2.37, 95% CI 1.50–3.72). Postoperative NLR measurements were not of prognostic significance.Conclusions
Elevated preoperative NLR is a reliable inflammatory biomarker for predicting AKI following cardiac surgery. 相似文献6.
7.
Sebastian Mondaca Walid K. Chatila David Bates Jaclyn F. Hechtman Andrea Cercek Neil H. Segal Zsofia K. Stadler Anna M. Varghese Ritika Kundra Marinela Capanu Jinru Shia Nikolaus Schultz Leonard Saltz Rona Yaeger 《Clinical colorectal cancer》2019,18(1):e39-e52
Background
Treatment of advanced anal squamous cell cancer (SCC) is usually with the combination of cisplatin and 5-fluorouracil, which is associated with heterogeneous responses across patients and significant toxicity. We examined the safety and efficacy of a modified schedule, FOLFCIS (leucovorin, fluorouracil, and cisplatin), and performed an integrated clinical and genomic analysis of anal SCC.Patients and Methods
We reviewed all patients with advanced anal SCC receiving first-line FOLFCIS chemotherapy – essentially a FOLFOX (leucovorin, fluorouracil, and oxaliplatin) schedule with cisplatin substituted for oxaliplatin – in our institution between 2007 and 2017, and performed deep sequencing to identify genomic markers of response and key genomic drivers.Results
Fifty-three patients with advanced anal SCC (48 metastatic; 5 unresectable, locally advanced) received first-line FOLFCIS during this period; all were platinum-naive. The response rate was 48% (95% confidence interval [CI], 32.6%-63%). With a median follow-up of 41.6 months, progression-free survival and overall survival were 7.1 months (95% CI, 4.4-8.6 months) and 22.1 months (95% CI, 16.9-28.1 months), respectively. Among all patients with advanced anal SCC that underwent sequencing during the study period, the most frequent genomic alterations consisted of chromosome 3q amplification (51%) and mutations in PIK3CA (29%) and KMT2D (22%). No genomic alteration correlated with response to platinum-containing treatment. Although there were few cases, patients with human papillomavirus-negative anal SCC did not appear to benefit from FOLFCIS, and all harbored distinct genomic profiles with TP53, TERT promoter, and CDKN2A mutations.Conclusions
FOLFCIS appears effective and safe as first-line chemotherapy in patients with advanced anal SCC and represents an alternative treatment option for these patients. 相似文献8.
9.
Oliver Sartor MD Daniel Heinrich MD Neil Mariados MD Maria José Méndez Vidal MD Daniel Keizman MD Camilla Thellenberg Karlsson MD Avivit Peer MD Giuseppe Procopio MD Stephen J. Frank MD Kalevi Pulkkanen MD Eli Rosenbaum MD Stefano Severi MD José Trigo MD Lucia Trandafir MD Volker Wagner MD Rui Li MS Luke T. Nordquist MD 《The Prostate》2019,79(14):1683-1691
10.